Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome: A retrospective study from The Korean Society of Hematology AML/MDS Working Party

The Korean Society of Hematology AML/MDS Working Party

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA. Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes. The median progression free survival(PFS) was 9.2 months (range 7.7-10.7 months) vs 28.9 months (range 22.6-35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group. Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA.

Original languageEnglish
Pages (from-to)79414-79424
Number of pages11
JournalOncotarget
Volume8
Issue number45
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Myelodysplastic Syndromes
Proxy
Hematology
Retrospective Studies
Disease-Free Survival
Survival
Treatment Failure
Disease Progression
Therapeutics
Multivariate Analysis
Economics

Keywords

  • Azacitidine
  • Decitabine
  • Discontinuation
  • Myelodysplastic syndrome
  • Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : A retrospective study from The Korean Society of Hematology AML/MDS Working Party. / The Korean Society of Hematology AML/MDS Working Party.

In: Oncotarget, Vol. 8, No. 45, 01.01.2017, p. 79414-79424.

Research output: Contribution to journalArticle

@article{b2fbc259e9084c7296686e0803c45bc8,
title = "Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome: A retrospective study from The Korean Society of Hematology AML/MDS Working Party",
abstract = "It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA. Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes. The median progression free survival(PFS) was 9.2 months (range 7.7-10.7 months) vs 28.9 months (range 22.6-35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group. Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA.",
keywords = "Azacitidine, Decitabine, Discontinuation, Myelodysplastic syndrome, Survival",
author = "{The Korean Society of Hematology AML/MDS Working Party} and Kim, {Da Jung} and Lee, {Ho Sup} and Moon, {Joon Ho} and Sohn, {Sang Kyun} and Kim, {Hyeoung Joon} and Cheong, {June Won} and Jo, {Deog Yeon} and Hawk Kim and Hyewon Lee and Bang, {Soo Mee} and Lee, {Won Sik} and Yong Park and Lee, {Mark Hong} and Lee, {Jae Hoon} and Bae, {Sung Hwa} and Kim, {Min Kyoung}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.18258",
language = "English",
volume = "8",
pages = "79414--79424",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

TY - JOUR

T1 - Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome

T2 - A retrospective study from The Korean Society of Hematology AML/MDS Working Party

AU - The Korean Society of Hematology AML/MDS Working Party

AU - Kim, Da Jung

AU - Lee, Ho Sup

AU - Moon, Joon Ho

AU - Sohn, Sang Kyun

AU - Kim, Hyeoung Joon

AU - Cheong, June Won

AU - Jo, Deog Yeon

AU - Kim, Hawk

AU - Lee, Hyewon

AU - Bang, Soo Mee

AU - Lee, Won Sik

AU - Park, Yong

AU - Lee, Mark Hong

AU - Lee, Jae Hoon

AU - Bae, Sung Hwa

AU - Kim, Min Kyoung

PY - 2017/1/1

Y1 - 2017/1/1

N2 - It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA. Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes. The median progression free survival(PFS) was 9.2 months (range 7.7-10.7 months) vs 28.9 months (range 22.6-35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group. Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA.

AB - It is often difficult to continue treatment with hypomethylating agent(HMA) in clinical practice because of problems such as toxicities, poor economics, etc. We compared clinical outcomes of those patients who continued HMA and those who discontinued HMA because of other causes, and evaluated factors associated with survival in those patients who discontinued HMA. Patients were divided into two groups: treatment failure, those who stopped treatment due to disease progression; and discontinuation, those who discontinued treatment because of other causes. The median progression free survival(PFS) was 9.2 months (range 7.7-10.7 months) vs 28.9 months (range 22.6-35.2) in the treatment failure and discontinuation groups, respectively (P < 0.001). In a multivariate analysis, a lower risk by WPSS was an independent predictive factor for a longer PFS, and a lower risk by WPSS and median number of HMA cycles greater than seven were independent predictive factors for longer overall survival(OS) only in the discontinuation group. Patients who discontinued HMA without disease progression showed a prolonged survival than those who failed HMA treatment. Especially, a lower risk by WPSS and longer duration of HMA treatment may be predictive factors for a longer PFS and OS in patients who discontinued HMA.

KW - Azacitidine

KW - Decitabine

KW - Discontinuation

KW - Myelodysplastic syndrome

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85030473531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030473531&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18258

DO - 10.18632/oncotarget.18258

M3 - Article

AN - SCOPUS:85030473531

VL - 8

SP - 79414

EP - 79424

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -